106.91 USD
+0.12 (+0.11%)
106.94 USD
+0.03 (+0.03%)
Overall VRNA gets a fundamental rating of 3 out of 10. We evaluated VRNA against 192 industry peers in the Pharmaceuticals industry. The financial health of VRNA is average, but there are quite some concerns on its profitability. VRNA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
VRNA had negative earnings in the past year.
VRNA had a negative operating cash flow in the past year.
In the past 5 years VRNA always reported negative net income.
In the past 5 years VRNA always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -14.17%, VRNA is doing good in the industry, outperforming 63.08% of the companies in the same industry.
VRNA has a Return On Equity of -29.18%. This is comparable to the rest of the industry: VRNA outperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.17% | ||
| ROE | -29.18% | ||
| ROIC | N/A |
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of VRNA (95.15%) is better than 96.41% of its industry peers.
The Profit Margin and Operating Margin are not available for VRNA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRNA has more shares outstanding
VRNA has more shares outstanding than it did 5 years ago.
VRNA has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 18.44 indicates that VRNA is not in any danger for bankruptcy at the moment.
The Altman-Z score of VRNA (18.44) is better than 90.26% of its industry peers.
A Debt/Equity ratio of 0.87 indicates that VRNA is somewhat dependend on debt financing.
VRNA has a worse Debt to Equity ratio (0.87) than 71.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 18.44 |
ROIC/WACCN/A
WACC9.28%
2.3 Liquidity
VRNA has a Current Ratio of 10.71. This indicates that VRNA is financially healthy and has no problem in meeting its short term obligations.
VRNA has a better Current ratio (10.71) than 83.08% of its industry peers.
VRNA has a Quick Ratio of 10.54. This indicates that VRNA is financially healthy and has no problem in meeting its short term obligations.
VRNA has a Quick ratio of 10.54. This is amongst the best in the industry. VRNA outperforms 83.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.71 | ||
| Quick Ratio | 10.54 |
3. Growth
3.1 Past
VRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.54%, which is quite impressive.
VRNA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.86% yearly.
EPS 1Y (TTM)36.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.77%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 57.72% on average over the next years. This is a very strong growth
Based on estimates for the next years, VRNA will show a very strong growth in Revenue. The Revenue will grow by 123.42% on average per year.
EPS Next Y123.97%
EPS Next 2Y73.8%
EPS Next 3Y64.23%
EPS Next 5Y57.72%
Revenue Next Year1008.75%
Revenue Next 2Y342.34%
Revenue Next 3Y211.05%
Revenue Next 5Y123.42%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
VRNA is valuated quite expensively with a Price/Forward Earnings ratio of 48.49.
Based on the Price/Forward Earnings ratio, VRNA is valued a bit cheaper than the industry average as 67.18% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 24.04. VRNA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 48.49 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as VRNA's earnings are expected to grow with 64.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.8%
EPS Next 3Y64.23%
5. Dividend
5.1 Amount
VRNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
106.91
+0.12 (+0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners80.77%
Inst Owner Change5.81%
Ins Owners4.64%
Ins Owner Change-1851.26%
Market Cap9.19B
Revenue(TTM)221.67M
Net Income(TTM)-81.19M
Analysts68.89
Price Target108.43 (1.42%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)75.16%
Min EPS beat(2)-4.58%
Max EPS beat(2)154.9%
EPS beat(4)1
Avg EPS beat(4)26.61%
Min EPS beat(4)-34.07%
Max EPS beat(4)154.9%
EPS beat(8)3
Avg EPS beat(8)-13.52%
EPS beat(12)4
Avg EPS beat(12)-12.45%
EPS beat(16)8
Avg EPS beat(16)2.57%
Revenue beat(2)2
Avg Revenue beat(2)24.91%
Min Revenue beat(2)9.73%
Max Revenue beat(2)40.08%
Revenue beat(4)4
Avg Revenue beat(4)58.05%
Min Revenue beat(4)8.73%
Max Revenue beat(4)173.67%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.55%
EPS NY rev (1m)2.01%
EPS NY rev (3m)147.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 48.49 | ||
| P/S | 41.47 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 33.04 | ||
| P/tB | 33.1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.99
EYN/A
EPS(NY)2.2
Fwd EY2.06%
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS2.58
BVpS3.24
TBVpS3.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.17% | ||
| ROE | -29.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.15% | ||
| FCFM | N/A |
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 96.14% | ||
| Cap/Sales | 0.48% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.71 | ||
| Quick Ratio | 10.54 | ||
| Altman-Z | 18.44 |
F-Score4
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)19.84%
Cap/Depr(5y)14.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.77%
EPS Next Y123.97%
EPS Next 2Y73.8%
EPS Next 3Y64.23%
EPS Next 5Y57.72%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1008.75%
Revenue Next 2Y342.34%
Revenue Next 3Y211.05%
Revenue Next 5Y123.42%
EBIT growth 1Y57.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year125.44%
EBIT Next 3Y118.37%
EBIT Next 5YN/A
FCF growth 1Y-39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.98%
OCF growth 3YN/A
OCF growth 5YN/A
VERONA PHARMA PLC - ADR / VRNA FAQ
Can you provide the ChartMill fundamental rating for VERONA PHARMA PLC - ADR?
ChartMill assigns a fundamental rating of 3 / 10 to VRNA.
Can you provide the valuation status for VERONA PHARMA PLC - ADR?
ChartMill assigns a valuation rating of 2 / 10 to VERONA PHARMA PLC - ADR (VRNA). This can be considered as Overvalued.
How profitable is VERONA PHARMA PLC - ADR (VRNA) stock?
VERONA PHARMA PLC - ADR (VRNA) has a profitability rating of 2 / 10.
Can you provide the financial health for VRNA stock?
The financial health rating of VERONA PHARMA PLC - ADR (VRNA) is 5 / 10.